Patritumab Deruxtecan provides a HER3-targeting antibody-drug conjugate (ADC) for cancer and oncology research. It combines the HER3-directed monoclonal antibody patritumab with a deruxtecan (DXd) topoisomerase I inhibitor payload. This conjugate supports studies of HER3-mediated targeting, ADC cytotoxicity, and targeted drug delivery.
Key Features and Benefits
- HER3-Targeting ADC: Combines a HER3-directed monoclonal antibody with a cytotoxic DXd payload for targeted cancer research.
- DXd Payload: Contains a potent topoisomerase I inhibitor that specifically supports studies of ADC-mediated cytotoxicity.
- HER3 Recognition: Supports investigation of HER3 expression, antibody binding, internalization, and tumor-targeting mechanisms.
- Cleavable Linker: Uses a protease-cleavable linker specifically designed to facilitate intracellular release of the DXd payload.
- High Drug-to-Antibody Ratio: Features a drug-to-antibody ratio of approximately 8, specifically supporting efficient payload delivery.
- Targeted Payload Delivery: Supports investigation of antibody-mediated DXd delivery to HER3-expressing cancer cells.
- Topoisomerase I Inhibition: DXd interferes with DNA replication and promotes DNA damage, specifically supporting cytotoxicity research.
Applications
- HER3-Positive Cancer Research: Supports studies involving tumor models expressing human epidermal growth factor receptor 3 (HER3).
- Non-Small Cell Lung Cancer Research: Useful for investigating HER3-targeted ADC activity in NSCLC models, including EGFR-mutated tumors.
- EGFR-Mutated Lung Cancer Research: Supports studies of HER3-directed ADC strategies in EGFR-mutated lung cancer models.
- Breast Cancer Research: Especially useful for investigating HER3 expression and ADC-mediated cytotoxicity in relevant breast cancer models.
- ADC Research: Supports investigation of antibody targeting, internalization, payload release, and cytotoxic activity.
- Targeted Cancer Research: Useful for studying antibody-mediated delivery of DXd to HER3-expressing cancer cells.
- Cell-Based Cancer Assays: Supports evaluation of HER3-dependent binding, cellular uptake, and cytotoxic responses.
- Mechanism-of-Action Studies: Supports investigation of HER3 targeting and DXd-mediated topoisomerase I inhibition.
Storage and Handling
- Storage: Store according to the product specification under recommended temperature conditions. Protect from excessive heat and repeated freeze-thaw cycles.
- Handling: Handle using appropriate procedures for antibody-drug conjugates and cytotoxic research materials. Maintain conditions that preserve antibody and conjugate stability.
Patritumab Deruxtecan combines HER3-directed antibody targeting with a DXd topoisomerase I inhibitor payload and specifically supports HER3-positive cancer, EGFR-mutated lung cancer, ADC, targeted drug delivery, and oncology research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
